These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 34064704)

  • 1. Personalized Medicine for Neuroblastoma: Moving from Static Genotypes to Dynamic Simulations of Drug Response.
    Han JZR; Hastings JF; Phimmachanh M; Fey D; Kolch W; Croucher DR
    J Pers Med; 2021 May; 11(5):. PubMed ID: 34064704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.
    Padovan-Merhar OM; Raman P; Ostrovnaya I; Kalletla K; Rubnitz KR; Sanford EM; Ali SM; Miller VA; Mossé YP; Granger MP; Weiss B; Maris JM; Modak S
    PLoS Genet; 2016 Dec; 12(12):e1006501. PubMed ID: 27997549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From the identification of actionable molecular targets to the generation of faithful neuroblastoma patient-derived preclinical models.
    Capasso M; Brignole C; Lasorsa VA; Bensa V; Cantalupo S; Sebastiani E; Quattrone A; Ciampi E; Avitabile M; Sementa AR; Mazzocco K; Cafferata B; Gaggero G; Vellone VG; Cilli M; Calarco E; Giusto E; Perri P; Aveic S; Fruci D; Tondo A; Luksch R; Mura R; Rabusin M; De Leonardis F; Cellini M; Coccia P; Iolascon A; Corrias MV; Conte M; Garaventa A; Amoroso L; Ponzoni M; Pastorino F
    J Transl Med; 2024 Feb; 22(1):151. PubMed ID: 38351008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Italian Precision Medicine in Pediatric Oncology: Moving beyond Actionable Alterations.
    Pastorino F; Capasso M; Brignole C; Giglio S; Bensa V; Cantalupo S; Lasorsa VA; Tondo A; Mura R; Sementa AR; Garaventa A; Ponzoni M; Amoroso L
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance.
    Levin M; Stark M; Ofran Y; Assaraf YG
    Cancer Cell Int; 2021 Jan; 21(1):53. PubMed ID: 33446189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multiscale orchestrated computational framework to reveal emergent phenomena in neuroblastoma.
    Borau C; Wertheim KY; Hervas-Raluy S; Sainz-DeMena D; Walker D; Chisholm R; Richmond P; Varella V; Viceconti M; Montero A; Gregori-Puigjané E; Mestres J; Kasztelnik M; García-Aznar JM
    Comput Methods Programs Biomed; 2023 Nov; 241():107742. PubMed ID: 37572512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroblastoma: the impact of biology and cooperation leading to personalized treatments.
    Owens C; Irwin M
    Crit Rev Clin Lab Sci; 2012; 49(3):85-115. PubMed ID: 22646747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastoma.
    Gustafson WC; Matthay KK
    Expert Rev Neurother; 2011 Oct; 11(10):1411-23. PubMed ID: 21955198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligand-targeted liposomal therapies of neuroblastoma.
    Pastorino F; Marimpietri D; Brignole C; Di Paolo D; Pagnan G; Daga A; Piccardi F; Cilli M; Allen TM; Ponzoni M
    Curr Med Chem; 2007; 14(29):3070-8. PubMed ID: 18220743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance.
    Duffy DJ; Krstic A; Halasz M; Schwarzl T; Konietzny A; Iljin K; Higgins DG; Kolch W
    Genome Med; 2017 Feb; 9(1):15. PubMed ID: 28187790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetics advancing personalized nanomedicine in cancer therapy.
    Liu S
    Adv Drug Deliv Rev; 2012 Oct; 64(13):1532-43. PubMed ID: 22921595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction.
    Chesler L; Goldenberg DD; Collins R; Grimmer M; Kim GE; Tihan T; Nguyen K; Yakovenko S; Matthay KK; Weiss WA
    Neoplasia; 2008 Nov; 10(11):1268-74. PubMed ID: 18953436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long range personalized cancer treatment strategies incorporating evolutionary dynamics.
    Yeang CH; Beckman RA
    Biol Direct; 2016 Oct; 11(1):56. PubMed ID: 27770811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology.
    Wienke J; Dierselhuis MP; Tytgat GAM; Künkele A; Nierkens S; Molenaar JJ
    Eur J Cancer; 2021 Feb; 144():123-150. PubMed ID: 33341446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Too many targets, not enough patients: rethinking neuroblastoma clinical trials.
    Fletcher JI; Ziegler DS; Trahair TN; Marshall GM; Haber M; Norris MD
    Nat Rev Cancer; 2018 Jun; 18(6):389-400. PubMed ID: 29632319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Therapies for Relapsed and Refractory Neuroblastoma.
    Zage PE
    Children (Basel); 2018 Oct; 5(11):. PubMed ID: 30384486
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.